SCHEMBL3065128

SCHEMBL3065128

Cc1c(F)cc(C(=O)Nc2ccc(Oc3cccc4c3CCN4CC(=O)N3CCN(Cc4ccc5c(c4)OCO5)CC3)nc2)c(F)c1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.43
KDM4E B2RXH2 5/20 0.41
ALDH1A1 P00352 4/20 0.41
HTT P42858 2/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
MAPT P10636 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
TDP1 Q9NUW8 3/20 0.41
LMNA P02545 5/20 0.40
HSD17B10 Q99714 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
ABCB1 P08183 1/20 0.40
CYP3A4 P08684 1/20 0.40
GAA P10253 1/20 0.40
ALK Q9UM73 1/20 0.39
USP2 O75604 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3052258 0.89 PRKAA2 (0.41) FAAHKDM4EALDH1A1HTTKMT2A
SCHEMBL3065125 0.85 FAAH (0.43) FAAHKDM4EALDH1A1HTTKMT2A
SCHEMBL3060416 0.84 MEN1 (0.49) FAAHALDH1A1HTTKMT2AMEN1
SCHEMBL3052257 0.83 FAAH (0.44) FAAHHTTNPC1TDP1LMNA
SCHEMBL3055931 0.82 KDM4E (0.48) FAAHKDM4EALDH1A1HTTKMT2A
SCHEMBL3047408 0.82 TDP1 (0.47) FAAHKDM4EALDH1A1HTTKMT2A
SCHEMBL3051209 0.81 MEN1 (0.48) KDM4EALDH1A1HTTKMT2AMEN1
SCHEMBL3061620 0.81 KDM4E (0.47) KDM4EALDH1A1HTTKMT2AMEN1
SCHEMBL3057193 0.80 LMNA (0.41) FAAHKDM4EALDH1A1HTTKMT2A
SCHEMBL3050849 0.79 ALDH1A1 (0.51) KDM4EALDH1A1HTTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551999-B2 Heterocyclic compound and pharmaceutical composition thereof OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-10-08 US disclosed
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-10-14 US disclosed
EP-2207773-A2 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF Otsuka Pharmaceutical Co., Ltd. (JP) 2010-07-21 EP disclosed
WO-2009057811-A2 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF COL1A1, COL2A1, COL14A1 FAAH 2709/4885KDM4E 2634/4885ALDH1A1 741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.